Warning: The NCBI web site requires JavaScript to function. more...
Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective.
Scherbaum WA, Goodall G, Erny-Albrecht KM, Massi-Benedetti M, Erdmann E, Valentine WJ.
Cost Eff Resour Alloc. 2009 May 5;7:9.
Related citations
PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK.
Valentine WJ, Bottomley JM, Palmer AJ, Brändle M, Foos V, Williams R, Dormandy JA, Yates J, Tan MH, Massi-Benedetti M; PROactive Study Group.
Diabet Med. 2007 Sep;24(9):982-1002. Epub 2007 Jun 25.
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL, Figgitt DP.
Pharmacoeconomics. 2004;22(6):389-411. Review.
Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting.
Valentine WJ, Palmer AJ, Lammert M, Nicklasson L, Foos V, Roze S.
Curr Med Res Opin. 2005 Dec;21(12):2063-71.
A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US.
St Charles M, Minshall ME, Pandya BJ, Baran RW, Tunis SL.
Curr Med Res Opin. 2009 Jun;25(6):1343-53. Erratum in: Curr Med Res Opin. 2009 Jun;25(6):1353.
Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland.
Brändle M, Azoulay M, Greiner RA.
Int J Clin Pharmacol Ther. 2007 Apr;45(4):203-20.
Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J, Jones J, Takeda A, Davidson P, Price A.
Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.
Acarbose in addition to existing treatments in patients with type 2 diabetes: health economic analysis in a German setting.
Roze S, Valentine WJ, Evers T, Palmer AJ.
Curr Med Res Opin. 2006 Jul;22(7):1415-24.
Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a german statutory healthcare perspective.
Neeser K, Lübben G, Siebert U, Schramm W.
Pharmacoeconomics. 2004;22(5):321-41. Review.
Continuous subcutaneous insulin infusion versus multiple daily injections of insulin: economic comparison in adult and adolescent type 1 diabetes mellitus in Australia.
Cohen N, Minshall ME, Sharon-Nash L, Zakrzewska K, Valentine WJ, Palmer AJ.
Pharmacoeconomics. 2007;25(10):881-97.
Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
Ray JA, Boye KS, Yurgin N, Valentine WJ, Roze S, McKendrick J, Tucker DM, Foos V, Palmer AJ.
Curr Med Res Opin. 2007 Mar;23(3):609-22.
The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M, Mealing S, Anderson R, Dean J, Stein K, Price A, Taylor RS.
Health Technol Assess. 2007 Nov;11(47):iii-iv, ix-248. Review.
Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.
Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. Review.
Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland.
Brändle M, Erny-Albrecht KM, Goodall G, Spinas GA, Streit P, Valentine WJ.
Int J Clin Pharmacol Ther. 2009 Aug;47(8):501-15.
[Cost-effectiveness of continuous subcutaneous insulin infusion therapy for type 1 diabetes].
Nørgaard K, Sohlberg A, Goodall G.
Ugeskr Laeger. 2010 Jul 5;172(27):2020-5. Danish.
Cost-effectiveness of switching to biphasic insulin aspart 30 from human insulin in patients with poorly controlled type 2 diabetes in South Korea.
Lee KH, Seo SJ, Smith-Palmer J, Palmer JL, White J, Valentine WJ.
Value Health. 2009 Nov-Dec;12 Suppl 3:S55-61.
A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK.
Tilden DP, Mariz S, O'Bryan-Tear G, Bottomley J, Diamantopoulos A.
Pharmacoeconomics. 2007;25(1):39-54. Erratum in: Pharmacoeconomics. 2007;25(3):237.
Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study.
Gaede P, Valentine WJ, Palmer AJ, Tucker DM, Lammert M, Parving HH, Pedersen O.
Diabetes Care. 2008 Aug;31(8):1510-5. Epub 2008 Apr 28.
Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.
Tunis SL, Willis WD, Foos V.
Curr Med Res Opin. 2010 Jan;26(1):163-75.
Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials.
Palmer AJ, Roze S, Valentine WJ, Smith I, Wittrup-Jensen KU.
Curr Med Res Opin. 2004 Nov;20(11):1729-46.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on